Lab Tests Online would not be possible without the financial support and commitment to public service of the following companies. Each company recognizes the importance of engaging patients through a greater understanding of testing and regularly supports the efforts of the laboratory profession.
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.
PROFESSIONAL CO-OP, an original model launched in 2001 to support the alternative and complementary health care community, provides appropriately licensed clinicians with access to major lab services for a fraction of the typical costs. There are no fees and no minimums. Our staff is knowledgeable, professional, and experienced in handling the issues and problems commonly seen in lab testing. PCS allows the clinician to focus on what’s most important, patient care, at substantial savings.
Bio-Rad Laboratories has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for clinical diagnostic customers. Known for our commitment to quality and customer service, we offer a broad diagnostic portfolio: Blood Bank Blood-group serology reagents and automation; Chromogenic Media; Diabetes, Hemoglobinopathy Testing; HIV tests for screening, rapid differentiation and supplemental tests; BioPlex® 2200 System, fully-automated, high-volume random-access, multiplex analyzer. EVOLIS™ microplate sytem. PhD™ System for EIA/IFA. Infectious disease and autoimmune disease methods and assays; Quality Control: Reliable, high quality materials, robust QC data management, connectivity solutions, QC educational series and the industry’s largest QC support team.
Fujirebio Diagnostics, Inc. is a world leader in the production of in vitro diagnostics and the gold standard manufacturer of cancer biomarker assays worldwide. Biomarkers available from Fujirebio Diagnostics include: CA125II™, CA19-9™, CA15-3®, ProGRP, NSE, SCC, S100, CA 242, CA72-4©, CYFRA21-1™, and HE4, the first FDA cleared biomarker in 25 years for ovarian cancer management. Now cleared in the US is ROMA™ (Risk of Malignancy Algorithm). ROMA™ combines CA125 + HE4 to compute likelihood of ovarian malignancy.
Randox is a global diagnostic solutions company headquartered in the UK with distribution in a further 130 countries. With 30 years of experience in this field, Randox has a strong research and development ethos ensuring innovative, high quality solutions are produced. The new Evidence Evolution is the world’s first random access biochip testing platform. Utilising Biochip Array Technology as developed by Randox, it offers revolutionary multiplexing of many routine and novel biomarkers. Arrays cover disease states such as cardiovascular disease, cancer, infectious diseases, respiratory as well as drugs of abuse and drug residue screening. The Randox portfolio also includes clinical chemistry analysers and reagents, including H-FABP and TxB Cardio Assays which are set to revolutionise cardiovascular healthcare. Quality Control, EQA programmes, IQC software and a full life science range complete the offering. All Randox products offer efficiency, flexibility, quality and cost-effectiveness to meet the needs of all laboratory types.
PAML is a medical reference laboratory serving physicians, hospitals, members of the community, employers, and other allied health professionals. Currently, PAML is ranked among the top clinical reference laboratories in the nation and is considered an industry leader in joint venture partnerships with community-based hospitals.